Acquisition will expand clinical pharmacology bed capacity and broaden Covance's access to special patient populations for Phase Ib/IIa studies.
PRINCETON, NJ-Covance Inc. has acquired the eight early phase clinical development sites of Radiant Research Inc. for approximately $65 million.
"Early phase clinical trials continue to be one of the biggest bottlenecks in the development of new medicines. These eight sites will expand Covance's early clinical service offering and advance our leadership position in delivering proof-of-concept packages that accelerates our clients' drug development projects," said Joe Herring, Covance Chairman and Chief Executive Officer.
"This investment will allow us to meet our clients' growing demand for high-science, first-in-human clinical trial services and address one of their toughest drug development challenges," said Wendel Barr, President of Early Development North America. "We welcome Radiant's experienced and talented staff to the Covance team. We look forward to integrating these new capabilities with our broad drug development portfolio, including our preclinical, bioanalytical, and cardiac safety services."
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.